NeoGenomics (NEO) Earnings Date & Reports

Key Takeaways

• NeoGenomics reported third quarter 2026 diluted earnings per share (EPS) of $0.07, topping the consensus estimate of $0.05 by $0.02.
• Revenue came in at roughly $209.3 million, above the $206.6 million consensus and up approximately 11% from $187.8 million a year earlier.
• Management issued full-year 2026 revenue guidance of $802 million to $806 million, framing continued double-digit top-line growth.
• Growth continues to be driven by next-generation sequencing (NGS) and minimal residual disease (MRD) testing, a key competitive battleground in precision oncology.
• For additional context on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated NEO pages.
• To discover automated trading strategies across the broader market, explore Trending AI Robots.

Earnings Context and Why It Matters

NeoGenomics is a leading oncology diagnostics provider that supports precision medicine through advanced testing services. Its third quarter 2026 results matter because investors are watching whether the company can sustain double-digit revenue growth in a rapidly expanding but increasingly competitive MRD testing market. NeoGenomics has now beaten consensus EPS estimates in six of its last eight quarters, and this report serves as a fresh test of whether that momentum, led by its RaDaR ST MRD assay, can continue following a Medicare coverage expansion in August for a third clinical indication. With shares having climbed sharply off their 52-week low, the quarter also carries weight for the stock's valuation debate.

Reported Results

NeoGenomics reported third quarter 2026 diluted EPS of $0.07, exceeding the consensus estimate of $0.05. Revenue reached approximately $209.3 million, above the $206.6 million analysts had projected and up about 11% from $187.8 million in the prior-year quarter, when the company reported EPS of $0.03.

For the first nine months of 2026, net revenue totaled roughly $597.6 million, compared with $537.2 million in the same period a year earlier. Management updated its full-year 2026 outlook, guiding to revenue of $802 million to $806 million, slightly above the consensus figure of approximately $805 million. The results reflect continued expansion in higher-value testing categories, particularly NGS and MRD, which remain central to the company's growth strategy.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors monitoring names like NeoGenomics and the broader precision oncology space, the AI Screener offers a streamlined way to surface relevant opportunities.

Market Reaction and Investor Sentiment

Heading into the report, sentiment around NeoGenomics was broadly constructive. Analysts rated the stock a consensus buy, with a mean price target of roughly $21.85 and no sell ratings among the 12 firms covering the company. Notably, BTIG upgraded the stock to buy from neutral earlier in the month, citing valuation that it viewed as inexpensive relative to specialty laboratory peers. The third quarter beat on both revenue and EPS reinforces the bull case that NeoGenomics has stabilized its operations and is converting diagnostic demand into profitable growth. Investor attention now turns to whether the double-digit revenue trajectory can be sustained as competition in MRD testing intensifies.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will focus on the durability of growth in NGS and MRD testing, the company's highest-value service lines. Management had previously guided to roughly 28% NGS revenue growth for the third quarter, and sustaining or accelerating that pace will be a central question in the quarters ahead.

Competition is another key factor. The MRD testing market represents an estimated $20 billion addressable opportunity, and larger rivals have recently launched competing assays. NeoGenomics has emphasized its strength in community oncology settings, where test menu breadth, turnaround time, and customer service can matter more than technology alone.

Finally, a leadership transition is on the horizon, with President Warren Stone expected to succeed CEO Tony Zook in January. Investors will monitor how this handoff shapes execution, while also watching margin trends, reimbursement dynamics, and whether full-year 2026 revenue guidance can be achieved at the upper end of the range.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations